A Trial Investigating CDK4/6 Inhibitors for the Treatment of Mantle Cell Lymphoma

Video

Selina Chen-Kiang, PhD, a professor of pathology and immunology at Weill Cornell Medical College, discusses the rationale of her phase I trial investigating the use of CDK4/6 inhibitors for the treatment of patients with mantle cell lymphoma.

Selina Chen-Kiang, PhD, a professor of pathology and immunology at Weill Cornell Medical College, discusses the rationale of her phase I trial investigating the use of CDK4/6 inhibitors for the treatment of patients with mantle cell lymphoma.

Chen-Kiang says the important part of using a CDK4/6 inhibitor is using combination therapies. For her trial, patients received a treatment combination of a CDK-4/6 inhibitor, palbociclib (Ibrance), plus the BTK inhibitor ibrutinib (Imbruvica).

Related Videos
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Hannah Choe, MD, an expert on GVHD
Corey Cutler, MD, MPH, an expert on GVHD
Related Content